Stryker Co. (NYSE:SYK) Shares Bought by Scotia Capital Inc.

Scotia Capital Inc. raised its position in shares of Stryker Co. (NYSE:SYK - Free Report) by 10.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 94,459 shares of the medical technology company's stock after acquiring an additional 9,089 shares during the period. Scotia Capital Inc.'s holdings in Stryker were worth $34,014,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in SYK. Kohmann Bosshard Financial Services LLC purchased a new stake in shares of Stryker during the 4th quarter worth about $25,000. Rakuten Securities Inc. grew its stake in Stryker by 618.2% during the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company's stock worth $28,000 after buying an additional 68 shares during the period. Centricity Wealth Management LLC purchased a new stake in Stryker during the fourth quarter worth approximately $30,000. BankPlus Trust Department purchased a new position in shares of Stryker in the 4th quarter valued at $33,000. Finally, Activest Wealth Management acquired a new position in shares of Stryker during the 4th quarter valued at $36,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director Allan C. Golston sold 2,458 shares of the firm's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the transaction, the director now directly owns 14,895 shares of the company's stock, valued at approximately $5,705,827.65. This trade represents a 14.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the transaction, the director now owns 3,642,075 shares of the company's stock, valued at $1,428,567,498. This represents a 5.24 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company's stock.

Remove Ads

Stryker Stock Performance

NYSE SYK traded down $6.50 during trading hours on Tuesday, reaching $346.92. The company's stock had a trading volume of 472,642 shares, compared to its average volume of 1,355,878. The stock has a market cap of $132.42 billion, a PE ratio of 44.71, a PEG ratio of 2.93 and a beta of 0.93. The business has a 50-day simple moving average of $374.63 and a 200 day simple moving average of $373.58. Stryker Co. has a 52 week low of $314.93 and a 52 week high of $406.19. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping analysts' consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the prior year, the company posted $3.46 earnings per share. Equities research analysts predict that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be issued a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.97%. Stryker's dividend payout ratio (DPR) is presently 43.30%.

Wall Street Analyst Weigh In

Several research firms have commented on SYK. Stifel Nicolaus raised their price objective on Stryker from $400.00 to $440.00 and gave the company a "buy" rating in a research report on Wednesday, January 29th. JMP Securities restated a "market perform" rating on shares of Stryker in a report on Tuesday, February 18th. StockNews.com cut shares of Stryker from a "buy" rating to a "hold" rating in a research report on Thursday, March 6th. Truist Financial lifted their price target on shares of Stryker from $409.00 to $413.00 and gave the stock a "hold" rating in a research note on Thursday, January 30th. Finally, JPMorgan Chase & Co. boosted their price target on Stryker from $420.00 to $445.00 and gave the stock an "overweight" rating in a research note on Wednesday, January 29th. Five analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. Based on data from MarketBeat.com, Stryker currently has a consensus rating of "Moderate Buy" and an average price target of $423.05.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.